Individualized PeMetRexed dOsing in lung cancER and mesothelioma patients to improVE treatment response and allow treatment of patients with impaired renal function – The IMPROVE study

Pemetrexed is a cornerstone in the treatment of lung cancer and mesothelioma. Optimized dosing of pemetrexed based on renal function instead of body surface area (BSA) is hypothesized to reduce pharmacokinetic variability in systemic exposure in patients with adequate renal function and even enable treatment in patients with impaired renal function. The overall goal of the IMPROVE-studies was to investigate individualized, safe dosing of pemetrexed without hampering efficacy.